Start-up Clinical Trial Company

Nature of the company :

• A clinical trial company headquartered in Bangalore and funded from the US.
• It established an impressive track record of helping clients achieve their goals in pivotal as well as early stage Proof of Concept (PoC) studies. It worked closely with clients on trial design and implementation to bring the multiple advantages of India to their early clinical development programs.

Specialties :

• Proof of Concept Studies, and pivotal oncology trials with extra-ordinary expertise in Oncology.

Other areas covered :

Background of the Start-up CEO :

• Vast experiences in the conduct of clinical research in India and the United States as well as the global management of various clinical research projects. He has served as the CEO of Clin Test International and Triesta Sciences, a clinical genomics company focused on RNA and DNA fingerprints in Oncology. While at the Harvard-MIT Clinical Research Centre, Cambridge, MA, he led a clinical research team focused on early stage clinical research. He is a graduate of St. John’s Medical College, India and the Sloan School of Management, MIT, Cambridge, MA. Age >35 years.

Mandate of e2e :

• Mentorship & Guidance
• To set up the complete people policies and procedures

Team & Duration :

Led by Ms. Yeshasvini Ramaswamy, MD, e2e, the team comprised of highly qualified consultants with backgrounds in Strategy, Law, Psychology, and Business Development. The project was executed over a 30 month period.

Results :

• Successful implementation of a ‘high quality’ delivery model that helped the company bag repeat orders
• Efficient model of communication and review developed to effectively engage multiple stakeholders (Investors, offices of the govt. of India, Core team, employees, customers)
• The company grew from a 5 member team to a 35 member team with multiple offices across India with strong employee ownership patterns
• Effective business mandate implementation that ensured profitable operations which helped attract further rounds of funding